Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials Inbar CohenHadar GoldvaserDaniel Shepshelovich Review Article 06 October 2021 Pages: 2879 - 2887
The optimal timing of radiotherapy in the combination treatment of limited-stage extranodal natural killer/T-cell lymphoma, nasal type: an updated meta-analysis Yue CuiYuyi YaoQuanguang Ren Review Article 27 October 2021 Pages: 2889 - 2900
Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience Mehran KarimiTahereh ZareiSezaneh Haghpanah Original Article 12 August 2021 Pages: 2901 - 2907
Circulating miRNAs and tissue iron overload in transfusion-dependent β-thalassemia major: novel predictors and follow-up guide Nashwa El-KhazragySafa MatboulySoha Abuelela Original Article 25 August 2021 Pages: 2909 - 2917
Correction to: Circulating miRNAs and tissue iron overload in transfusion-dependent β-thalassemia major: novel predictors and follow-up guide Nashwa El-KhazragySafa MatboulySoha Abuelela Correction 06 October 2021 Pages: 2919 - 2919
The anemia-independent impact of myelodysplastic syndromes on health-related quality of life Hanneke J. C. M. WoutersAnnette Conrads-Frankon behalf of the MDS-RIGHT partners Original Article Open access 02 September 2021 Pages: 2921 - 2932
The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia Jasmin WellbrockLena BehrmannWalter Fiedler Original Article Open access 01 August 2021 Pages: 2933 - 2941
Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells Julian BaumeisterTiago MaiéDeniz Gezer Original Article Open access 14 August 2021 Pages: 2943 - 2956
Phase II study of single-agent nivolumab in patients with myelofibrosis Iman Abou DalleHagop KantarjianSrdan Verstovsek Original Article 05 August 2021 Pages: 2957 - 2960
Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study Xiao-Xiao WangYan Gaoon behalf of the Lymphoma Committee, Chinese Anti-Cancer Association (CACA) Original Article 31 July 2021 Pages: 2961 - 2968
Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis. Guillermo VillacampaRodrigo DienstmannPau Abrisqueta Original Article 10 August 2021 Pages: 2969 - 2978
Bone marrow tracer uptake pattern of PET-CT in multiple myeloma: image interpretation and prognostic value Jing LiHui TanPeng Liu Original Article 20 August 2021 Pages: 2979 - 2988
Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry Kota SatoKiyoshi OkazukaKenshi Suzuki Original Article 25 August 2021 Pages: 2989 - 2995
Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease Ignacio IsolaDavid F. MorenoCarlos Fernández de Larrea Original Article 31 August 2021 Pages: 2997 - 3005
Prevalence of hypogammaglobulinemia and its management with subcutaneous immunoglobulin supplementation in patients after allogeneic hematopoietic stem cell transplantation—a single-center analysis Ewa Karakulska-PrystupiukJadwiga Dwilewicz-TrojaczekWiesław Wiktor Jędrzejczak Original Article Open access 03 September 2021 Pages: 3007 - 3016
The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia Masamitsu YanadaTakaaki KonumaShingo Yano Original Article 03 September 2021 Pages: 3017 - 3027
Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II–IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group Shun-ichi KimuraMasaharu TamakiHideki Nakasone Original Article 07 September 2021 Pages: 3029 - 3038
Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy Wenjiao TangYangfan XuBing Xiang Letter to the Editor 02 September 2020 Pages: 3039 - 3040
Stem cell transplantation for hemoglobinopathy Vila Real Justin HasenkampJoachim RiggertGerald Wulf Letter to the Editor Open access 03 September 2020 Pages: 3041 - 3042
Coexistence of MYC/BCL2 double-hit of t(8;14)(q24;q32) and t(14;18)(q32;q21) and that of t(8;22)(q24;q11) and t(14;18) in advanced-stage high-grade B cell lymphoma Kayo TakeokaMiho NakagawaHitoshi Ohno Letter to the Editor 07 September 2020 Pages: 3043 - 3045
Circulating blastoid cells: acute leukemia, prolymphocytic leukemia, or something else? Yue ZhaoCatherine RehderEndi Wang Letter to the Editor 15 September 2020 Pages: 3047 - 3048
Temozolomide showed rapid activity in a patient with refractory CNS monomorphic epitheliotropic T cell lymphoma Pui-Lun YipChing-Pong LamSze-Man June Lau Letter to the Editor 25 September 2020 Pages: 3049 - 3050
Caplacizumab: frequent local skin reactions Jessica KaufeldPaul T. BrinkkoetterLinus A. Völker Letter to the Editor Open access 30 September 2020 Pages: 3051 - 3052
Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma Donald C. MooreViera NelsonAlaa Muslimani Letter to the Editor 01 October 2020 Pages: 3053 - 3055
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma Tarek H. MouhieddineSamir ParekhDeepu Madduri Letter to the Editor 02 October 2020 Pages: 3057 - 3060
EBV+ posttransplant lymphoproliferative disease of the retina presenting as cytomegalovirus retinitis Ian Y. WongWing-Lau HoYok-Lam Kwong Letter to the Editor 03 October 2020 Pages: 3061 - 3063
Cutaneous botryomycosis mimicking ecthyma gangrenosum in a patient treated with ibrutinib Ana Pulido-PérezMarta Bergón-SendínFernando Carretero-López Letter to the Editor 07 October 2020 Pages: 3065 - 3066
Successful myeloablative unrelated bone marrow transplantation for relapsed intravascular large B cell lymphoma after autologous peripheral blood stem cell transplantation Yoko MiuraJun OoiNaoki Shirafuji Letter to the Editor 22 October 2020 Pages: 3067 - 3069
Plasma cell myeloma with pure lymphocyte-like morphology Kyoungyul LeeSook Won RyuJin Ho Paik Letter to the Editor 02 November 2020 Pages: 3071 - 3073
Clonal IgH gene rearrangements identify Richter’s transformation to diffuse large B cell lymphoma Disha DalelaJacob R. BledsoeShyam A. Patel Letter to the Editor 07 November 2020 Pages: 3075 - 3077
Cutaneous marginal zone lymphoma following anthrax vaccination Jocelyn B. ChandlerReid WaldmanEllice Y. Wong Letter to the Editor 16 November 2020 Pages: 3079 - 3080
Questioning the association between ABO type and outcomes in patients with COVID-19 Jori E. MayGerald McGwin JrMarisa B. Marques Letter to the Editor 17 November 2020 Pages: 3081 - 3082
Correction to: Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab Ka-Won KangHyemi MoonYong Park Correction 07 October 2021 Pages: 3083 - 3083